Terlipressin is a vasopressin analogue with potent vasoactive properties. Terlipressin is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin exerts anti-inflammatory and anti-oxidative effects. Terlipressin has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research.
IC50&Target
Vasopressin V1 receptor
体外研究
Terlipressin (25 nM; 24-72 hours; IEC-6 cells) treatment significantly improves cell viability, proliferation and apoptosis in IEC-6 cells.
Terlipressin inhibits the secretion of TNF-α and 15-F2t-isoprostane from IEC-6 cells following oxygen and glucose deprivation/re-oxygenation (OGD/R). Terlipressin administration following OGD attenuates OGD/R-induced cell damage via the PI3K signaling pathway.
Cell Proliferation Assay
Cell Line:
IEC-6 cells induced by oxygen and glucose deprivation/re-oxygenation (OGD/R)
Concentration:
25 nM
Incubation Time:
24 hours, 48 hours, 72 hours
Result:
Significantly increased the proliferation of IEC-6 cells.
体内研究
Using a mouse nonlethal hepatic ischemia-reperfusion (IR) model, Terlipressin administration significantly ameliorates IR-induced liver apoptosis, necrosis and inflammation.
分子式
C52H74N16O15S2
分子量
1227.37
CAS号
14636-12-5
中文名称
特利加压素
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
溶解性数据
In Vitro:
DMSO : 100 mg/mL (81.48 mM; Need ultrasonic)
配制储备液
浓度溶剂体积质量
1 mg
5 mg
10 mg
1 mM
0.8148 mL
4.0738 mL
8.1475 mL
5 mM
0.1630 mL
0.8148 mL
1.6295 mL
10 mM
0.0815 mL
0.4074 mL
0.8148 mL
In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: